SCHEMBL28519780

SCHEMBL28519780

Cn1ncc(Cl)c1-c1ncc(C(=O)NC(CN)Cc2cccc(F)c2)o1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 7/20 0.76
AKT2 P31751 4/20 0.76
AKT3 Q9Y243 4/20 0.76
PRKCA P17252 3/20 0.68
ROCK1 Q13464 3/20 0.68
ROCK2 O75116 2/20 0.68
PRKCB P05771 2/20 0.68
PRKACA P17612 2/20 0.68
PRKACB P22694 2/20 0.68
PKN1 Q16512 2/20 0.68
PRKD2 Q9BZL6 2/20 0.68
CIT O14578 1/20 0.68
SGK1 O00141 1/20 0.62
PRKD3 O94806 1/20 0.62
LATS1 O95835 1/20 0.62
PRKCG P05129 1/20 0.62
RPS6KB1 P23443 1/20 0.62
PRKCH P24723 1/20 0.62
MARK3 P27448 1/20 0.62
PRKCI P41743 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1592171 1.00 AKT1 (0.76) AKT1AKT2AKT3PRKCAROCK1
SCHEMBL1592316 0.86 AKT1 (0.60) AKT1AKT2AKT3PRKCAROCK1
SCHEMBL1529501 0.86 AKT1 (1.00) AKT1AKT2AKT3PRKCAROCK1
SCHEMBL1529667 0.85 AKT1 (0.86) AKT1AKT2AKT3PRKCAROCK1
SCHEMBL1591736 0.85 AKT1 (0.59) AKT1AKT2AKT3PRKCAROCK1
SCHEMBL674282 0.85 AKT1 (0.69) AKT1AKT2AKT3PRKCAROCK1
SCHEMBL1529323 0.84 AKT1 (0.83) AKT1AKT2AKT3PRKCAROCK1
SCHEMBL12766573 0.83 AKT1 (0.74) AKT1AKT2AKT3PRKCAROCK1
SCHEMBL28526551 0.83 AKT1 (0.76) AKT1AKT2AKT3PRKCAROCK1
SCHEMBL1591685 0.83 AKT1 (0.76) AKT1AKT2AKT3PRKCAROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113365610-A Methods of making and delivering bisantrene formulations 现代化制药公司 2021-09-07 CN disclosed
CN-112472699-A Combination methods for improving the therapeutic benefit of bisantrene and derivatives 种族肿瘤学公司 2021-03-12 CN disclosed